Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study
JMIR Research Protocols · 2024
DOI: 10.2196/64950 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift JMIR Research Protocols, 2024. Verfasst von Zhiqiang Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Cryosurgery, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical.
Objective
This study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC.
Methods
This is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded.
Results
The project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027.
Conclusions
This study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. Trial Registration ClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 International Registered Report Identifier (IRRID) PRR1-10.2196/64950
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Zhiqiang Gao, Jiajun Teng, Rong Qiao, Jialin Qian, Feng Pan, Meili Ma, Jun Lu, Bo Zhang, Tianqing Chu, Hua Zhong
Zitieren
APA
Gao, Z., Teng, J., Qiao, R., Qian, J., Pan, F., Ma, M., Lu, J., Zhang, B., Chu, T., & Zhong, H. (2024). Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study. JMIR Research Protocols. https://doi.org/10.2196/64950
Vancouver
Gao Z, Teng J, Qiao R, Qian J, Pan F, Ma M, et al. Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study. JMIR Research Protocols. 2024. doi:10.2196/64950
BibTeX
@article{Gao2024,
author = {Gao, Zhiqiang and Teng, Jiajun and Qiao, Rong and Qian, Jialin and Pan, Feng and Ma, Meili and Lu, Jun and Zhang, Bo and Chu, Tianqing and Zhong, Hua},
title = {Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non–Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study},
journal = {JMIR Research Protocols},
year = {2024},
doi = {10.2196/64950}
}
EUVIMED